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 Crystallization experiments and transient kinetic methods were used to 
characterize the first 75 amino acid segment of smooth muscle myosin light chain kinase 
(MLCK N1-75). As of now, the exact mechanism by which MLCK interacts with 
actomyosin complexes in smooth muscle is not well-understood because there is no high-
resolution 3-dimensional structure of MLCK available. In this project, the crystallization 
of the actin-binding domain of MLCK (called N1-75) with glutathione S-transferase 
(GST) was attempted in order to provide such a model. Polyethylene glycol and 
ammonium sulfate, within a pH range of 6.5 to 8.0, seemed to be the most promising 
precipitants to induce crystallization. Observation of crystallization setups with these 
paramenters showed no definitive results, and crystallization was not successful. Future 
experiments should attempt to increase protein quality before crystallization by removing 
the GST tag and achieving higher protein concentration. In addition to the crystallization 
experiments, transient kinetic methods were used to characterize MLCK N1-75 
interactions with actin and smooth muscle myosin subfragment 1 (S1). It was found that 
MLCK N1-75, when mixed with actin, decreased the rate at which actin binds S1. This 





Table of Contents 
Abstract …………………………………………………………………………………... i 
Table of Contents ………………………………………………………………………... ii 
Introduction …………………………………………………………………………….... 1 
Methods ………………………………………………………………………………..… 2 
Results ………………………………………………………………………………….... 9 





 Smooth muscle is found in the walls of blood vessels, the gastrointestinal tract, 
the respiratory tract, and many other areas in the body. Poor regulation of smooth muscle 
results in abnormal contraction, which can lead to a diverse range of health conditions 
including asthma and cardiovascular disease (Leguillette et al., 2009) (Yuan et al., 2014). 
Smooth muscle contraction is regulated by phosphorylation of the regulatory light chain 
of myosin II by myosin light chain kinase (MLCK) (Adelstein & Klee, 1981). The 
structurally complex MLCK contains multiple domains that each contribute to its 
function as a kinase (Hong et al., 2011). Currently, there is no high resolution 3-
dimensional structure of MLCK. The successful crystallization and x-ray crystallographic 
analysis of MLCK would serve as the basis for understanding the exact mechanism by 
which MLCK interacts with actomyosin complexes in smooth muscle. 
 MLCK is a long and flexible protein: it contains at least seven domains for 
binding to myosin, actin, and calmodulin as shown in Figure 1 (Hong et al., 2011). The 
sheer size of MLCK makes it unfeasible to crystallize the entire protein all at once; 
therefore, the focus of this research will be on the first 75 residues of the amino terminus 
which is thought to contain an actin-binding domain (referred to as MLCK N1-75). Prior 
research has shown that MLCK N1-75 is necessary and sufficient for high affinity 
binding to actin due to three DFRxxL motifs (Smith et al., 1999). Binding to actin allows 
MLCK to stay localized to myofilaments so that the enzyme can rapidly phosphorylate 
myosin to induce contraction (Smith & Stull, 2000). It also anchors MLCK so that the 
enzyme does not sterically hinder myosin during contraction. Transient kinetic methods 
using stopped-flow spectroscopy will be used to further characterize MLCK N1-75 
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interactions with actin. Specifically, it will be tested whether or not MLCK N1-75 
competes with smooth muscle myosin subfragment 1 (S1) for the same binding site on 
actin. This thesis reports the purification of MLCK N1-75, the crystallization 
experiments, and the actin:N1-75 binding studies.  
 
 
Figure 1. Domain structure of smooth muscle MLCK (from Hong et al., 2011) 
The focus of this research is on the N1-75 segment of MLCK which constitutes the 




Preparation of MLCK N1-75 
 MLCK N1-75 with glutathione S-transferase (GST) was expressed using E.coli in 
Dr. Christine Cremo’s lab. Cells from a transformed stock were plated and incubated at 
37°C overnight. Viable colonies were selected and transferred into fresh LB broth. Cells 
were allowed to grow until an OD reading of approximately 0.4. Cells were induced to a 
final concentration of 0.1mM IPTG. Cells were lysed using lysozyme. DTT was added to 
a final concentration of 5mM. Cells were spun at 100K rpm for 30min. The collected 
supernatant contained MLCK N1-75 GST. The GST affinity tag allowed it to be purified 
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using glutathione affinity chromatography on the ÄKTA pure FPLC (fast protein liquid 
chromatography) system. The MLCK N1-75 GST lysate was injected into GE’s GSTPrep 
FF 16/10 column. The column required phosphate buffered saline as the binding buffer. 
Once the lysate was pushed through the column (and all of the waste was eluted), a 
glutathione elution buffer was used to elute MLCK N1-75 GST from the column (Fig. 
2a). The fractions containing the protein were pooled and concentrated by precipitation 
with 70% ammonium sulfate and re-suspending and dialyzing in HMM buffer. Gel 
electrophoresis was conducted to verify that the size of the collected protein was 
approximately 37kDa (Fig. 2b). 
Initial Crystallization Setups 
 After purification, MLCK N1-75 GST was placed into hanging drop vapor 
diffusion setups to induce supersaturation and crystallization (McPherson & Gavira, 
2013). The Crystal Screen kits from Hampton Research were used for the five 
crystallization plates labeled N75-GST 1 through 5, respectively. The kits contain sparse 
matrix screens which sample a variety of salts, polymers, organics, and pH levels (see 
Tab. 1 for reagent formulations). The crystallization setups were stored at 4°C and left to 
equilibrate against the reservoir solution. Growth patterns of each setup were routinely 





Table 1. Hampton Research Crystal Screens 1 and 2 reagent formulations 
For the initial screens, 98 hanging drop setups were made to accommodate all of the 









Optimized Crystallization Setups 
 Crystallization experiments were evaluated using a scale ranging from 1 (clear, no 
precipitate, no crystals) to 9 (large crystals) (Tab. 2). Conditions that produced heavy 
precipitate were eliminated from future experiments. After observing each hanging drop 
in the initial crystal screens, new crystallization setups were made using optimized 
parameters. Observation of protein precipitation in the initial setups showed that a pH 
range of 6.5 to 7.5 with polyethylene glycol or ammonium sulfate as the precipitant 
seemed most likely to induce crystal growth (Tab. 3). Five crystallization plates with 
optimized parameters were created (Tab. 4). The first three (labeled N75-GST 6, 7, & 8 
respectively) used varying polymer lengths and concentrations of polyethylene glycol as 
the precipitant. The next two (N75-GST 9 & 10) used varying concentrations of 
ammonium sulfate as the precipitant and sodium chloride as an added salt. All of these 
setups were kept at 4°C and within a pH range of 6.5 to 8.0 in 0.1M HEPES buffer. 
These hanging drop setups were left to equilibrate, and they were periodically observed 
using light microscopy. The crystallization parameters resulting in the most promising 




Table 2. Scoring scale for crystallization setups  
This scale ranks typical observations in crystallization experiments (images from 
Hampton Research Crystal Screen User Guide). 
 
Score Observation Example 
1 Clear drop 
 
2 Phase separation 
 
3 Regular granular 
precipitate 
 
4 Birefringent precipitate or 
microcrystals 
 




6 Needles (1D growth) 
  
7 Plates (2D growth) 
 
8 Single crystals (3D growth 
< 0.2mm) 
 







Preparation of Proteins 
 MLCK N1-75, pyrene-actin (Pyr-actin), and myosin subfragment 1 (S1) were 
prepared in Dr. Cremo’s lab. MLCK N1-75 was expressed and purified using the method 
described above. Pyr-actin was prepared by isolating rabbit skeletal muscle actin and 
labeling with pyrene at cys-374 (Criddle et al., 1985). The cys-374 pyrene is a useful 
probe because it is located in the myosin binding site on the actin filament. As the pyrene 
fluorescence is quenched upon myosin binding, pyrene fluorescence measurements can 
be used to measure the rate and extent of myosin binding and release. S1 was prepared by 
isolating smooth muscle myosin from gizzard and digesting with V8 protease (Ikebe & 
Hartshorne, 1985). 
Stopped-flow Spectroscopy 
 Experiments were done in 150mM KCl, 4mM MgCl2, 2mM EGTA, 1mM DTT, 
25mM imidazole, pH 7.0 at 25°C using a Hi-Tech stopped-flow spectrophotometer with 
a mercury lamp. Pyrene fluorescence was excited at 365nm, and the emission was 
detected after passing through a KV 399 cutoff filter. For the control, 0.25μM Pyr-actin 
was rapidly mixed with 0.25μM S1 and the fluorescence change was observed. For the 
experimental trial, 0.25μM Pyr-actin was pre-mixed with 2μM MLCK N1-75 and then 
mixed with 0.25μM S1 and the fluorescence change was observed. All listed 
concentrations represent final values after mixing. The results shown are an average of 






Figure 2a. FPLC of N1-75 GST on GST 16/10 column 
50ml of cell extract containing MLCK was loaded onto the GST 16/10 column. The 
binding buffer was phosphate buffered saline, and the elution buffer was 50mM Tris-











Figure 2b. SDS-PAGE results for fractions 24-27 from FPLC 
Lanes 2-5 contain 10μl of fractions 24, 25, 26, and 27 respectively. Lanes 6-7 contain 
20μl amounts of fractions 24, 25, 26, and 27 respectively. Lane 1 contains the molecular 

























































Table 3. Initial crystallization setups observed to have favorable parameters 
Observations in the most promising initial screens approximately five weeks after the 
date of setup. 
 
Well # Salt Buffer Precipitant Observation 
Crystal Screen 2: 
#28 







Crystal Screen 2: 
#32 







Crystal Screen 2: 
#37 









Crystal Screen 2: 
#38 









Crystal Screen 2: 
#48 












Table 4. Formulations for optimized crystallization setups 
The parameters of these optimized plates were based on what appeared most likely to 
induce crystal growth in the initial screens (Table 3).  
 
Plate ID# Salt with 
concentration 
range 




N75-GST 6 None 0.1M HEPES, pH 
6.5-8.0 
Polyethylene glycol 
(PEG) 5000, 10-25% 
N75-GST 7 None 0.1M HEPES, pH 
6.5-8.0 
PEG 8000, 10-25% 
N75-GST 8 None 0.1M HEPES, pH 
6.5-8.0 
PEG 20000, 10-25% 












Table 5. Optimized crystallization setups observed to have favorable parameters 
Observations in the most promising optimized screens approximately two to three weeks 
after the date of setup. 
 
Plate ID#: Well 
# 
Salt Buffer Precipitant Observation 










N75-GST 6: #16 None 0.1M HEPES, 
pH 7.5 




N75-GST 7: #8 None 0.1M HEPES, 
pH 7.0 




N75-GST 7: #18 None 0.1M HEPES, 
pH 7.5 
25% PEG 8000 Slight 
spherulites and 
microcrystals 
N75-GST 8: #23 None 0.1M HEPES, 
pH 8.0 
22% PEG 20000 Slight 
spherulites 

































Figure 3. N-75 binds to actin filaments and reduces the rate of S1 binding to actin.  
0.25μM S1 was mixed with 0.25μM Pyr-actin (red  transient) and with 0.25μM Pyr-actin, 
2μM MLCK N1-75 (blue transient).  All concentrations are after mixing. kobs  for S1 
binding in the absence of N-75 was 0.22 s-1. With N-75 pre-mixed with pyr-actin, kobs  for 














The purification of MLCK N1-75 from the cell lysate was successful as shown in 
Figure 2. In Figure 2a, fractions 24-27 from the initial peak after the glutathione elution 
buffer was run through the GSTPrep FF 16/10 column. Figure 2b shows that the fractions 
each contained protein that was 37kDa in size, consistent with the known size of the 
MLCK N1-75-GST construct. Therefore, these fractions were collected and pooled. The 
UV absorbance beyond fraction 27 is caused by the presence of glutathione from the 
glutathione elution buffer.  
After the purified protein was placed into the initial crystallization screens, five 
individual setups were selected based on light microscope observations of the protein’s 
interaction with the well reagent (Tab. 3). In all of these setups, spherulites were 
observed. Microcrystals, phase separation, and small needles were also observed in 
individual setups. The trends found in the parameters of these five setups were used to 
formulate the optimized crystallization plates (Tab. 4). 0.1M HEPES with a pH around 
7.5 was seen to be most ideal for crystal growth, so the optimized plates all used 0.1M 
HEPES within a pH range of 6.5 to 8.0. Plates N75-GST 6, 7, and 8 used varying 
concentrations and lengths of polyethylene glycol because it was found to be the most 
common ideal precipitant. Plates N75-GST 9 and 10 used ammonium sulfate as the 
precipitant and sodium chloride as an added salt because these reagents were also 
observed to induce the growth of spherulites. 
Table 5 shows the most promising results after two to three weeks of allowing the 
protein to equilibrate against the optimized formulations. These selected setups were 
observed to contain slight formations of spherulites, microcrystals, or both. These 
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observations are promising in terms of overall crystal growth; however, none of the 
optimized setups show evidence of single crystal formation.  
Overall, crystallization of MLCK N1-75 has not yet been successful. The fact that 
crystallization is an empirical process makes it difficult to predict the best parameters for 
crystallization. Even with the perfect parameters, crystallization can take well over three 
weeks for certain proteins. Future experiments should take into consideration the 
parameters outlined in Table 5. Further optimization consisting of minor changes in the 
parameters may lead to crystal growth. Future trials should also attempt to crystallize 
MLCK N1-75 after achieving higher protein concentration and removing the GST tag 
because, then, the protein sample would be more pure and more susceptible to 
crystallization. The initial crystal screens also showed some promising observations for 
reagents buffered at a pH of 9.0, so future experiments should attempt to crystallize 
MLCK N1-75 at more alkaline conditions in BICINE or TRICINE buffer with 
precipitants such as polyethylene glycol. 
Figure 3 shows the results of the transient kinetic experiments. When 0.25μM S1 
was added to 0.25μM Pyr-actin alone, the rate of fluorescence decrease (kobs = 0.22) was 
much higher than when S1 was added to 0.25μM Pyractin pre-mixed with 2μM MLCK 
N1-75 (kobs = 0.035). These results indicate that the presence of MLCK N1-75 in solution 
with actin slows down the rate of S1 binding to actin. The implication is that actin, S1, 
and MLCK N1-75 interactions follow the scheme shown in Figure 4 below. Essentially, 
MLCK N1-75 appears to share a binding site with S1 for actin. MLCK N1-75 must 
dissociate from this binding site before S1 can interact with actin; therefore, the rate of S1 
binding is slowed when MLCK N1-75 is in solution with actin. It was not possible to 
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repeat this experiment due to abnormalities in the quality of proteins in later trials which 
resulted in irregular transients. Regardless, this experiment serves as a starting point for 
more transient kinetics experiments with MLCK N1-75. Future experiments should 
attempt to repeat the trials described here and also use varying concentrations of MLCK 




Figure 4. Actin interactions with S1 and MLCK N1-75 
This scheme outlines how MLCK N1-75 and S1 may share the same binding site on 
actin. It explains why the presence of MLCK N1-75 in solution with actin decreases the 
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